Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Longeveron Inc (LGVNR)

Longeveron Inc (LGVNR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update

LGVN : 1.8500 (-1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

LGVN : 1.8500 (-1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

LGVN : 1.8500 (-1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

LGVN : 1.8500 (-1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

LGVN : 1.8500 (-1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

LGVN : 1.8500 (-1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

LGVN : 1.8500 (-1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

LGVN : 1.8500 (-1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron (NASDAQ: LGVN; LGVNR) Study Survival Data Reported at AHA’s Scientific Sessions

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS),...

LGVNR : 0.0005 (-37.50%)
LGVN : 1.8500 (-1.07%)
Longeveron (NASDAQ: LGVN; LGVNR) Announces Plans to Release Q3 2023 Financial Report

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, has announced plans to report its financial results...

LGVNR : 0.0005 (-37.50%)
LGVN : 1.8500 (-1.07%)

Barchart Exclusives

Disney Stock: Is DIS Still a Buy after Rallying 18% in a Month?
Disney shares have risen considerably since the company released its fiscal Q4 2024 earnings earlier this month. The stock has room to run higher into 2025 also, given its growth prospects and reasonable valuations. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar